‘Baby in a bubble’ pioneer has leukaemia

December 18, 2007

‘Baby in a bubble’ pioneer has leukaemia

Last Updated:4:26pm GMT 18/12/2007

A child undergoing pioneering gene therapy for what has become known as “baby in the bubble syndrome” has developed leukaemia.

Great Ormond Street Hospital has announced that the boy, who was born with no immune system, has developed the chronic bone marrow disease two years after successful treatment for X-SCID.

Affected children produce no lymphocytes and have no natural defence against infection, meaning they must be kept isolated from the outside world.

X-SCID affects only boys and is caused by a single faulty gene.

In the first trial of its kind in Britain, 10 babies with two types of potentially fatal immune system diseases were given the treatment.

Medics in the UK knew that there was a risk of the children developing leukaemia as a result of the treatment, but the boy, who is three years old, has been the first to do so.

A trial in France of a similar therapy was stopped in 2002 after four of eleven children developed leukaemia.

Professor Adrian Thrasher and Professor Bobby Gaspar, consultant immunologists on the gene therapy programme, said in a statement: “As with any medical treatment there are associated side-effects.

“The development of leukaemia is now a recognised side-effect in this study, though the risks are balanced by the severity of the condition and the lack of good alternative treatments for X-SCID.

“This first study is now closed to recruitment while safer improved formulations of the genetic medicine are being prepared for clinical trials next year at several centres including Great Ormond Street.”

They added: “Every child matters.

“Families are counselled very carefully before taking part in these treatments.

“Gene therapy appears to offer a less intrusive treatment for those patients without a good bone marrow donor and, if we continue to make advances, may become the treatment of choice.”

He added: “All patients are monitored carefully as part of their care plan.”

Affected children are likely to die within a year without a bone marrow transplant.

Gene therapy involves a working copy of the defective gene being placed in the child’s bone marrow cells and these are then returned to the child.

Great Ormond Street has been working with the regulator, the Gene Therapy Advisory Committee (GTAC), since the discovery of the boy’s condition at the end of last month.

Professor Martin Gore, GTAC chairman, said: “My sympathy goes out to the child who has developed leukaemia following gene therapy for X-linked SCID and their family.

“I also feel for the nurses, doctors and researchers in the gene therapy team at GOSH who are utterly dedicated to helping children with serious life-threatening diseases.

“They are a highly regarded and professional group who have counselled families extensively about the risks of gene therapy, including the possibility of the development of leukaemia.

“I know that this child is in good hands and that colleagues at GOSH are doing everything possible to treat this child’s leukaemia successfully.”

linkback url: http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2007/
12/18/nbubble118.xml


Boy Living in Bubble Develops Leukemia From Experimental Therapy

December 18, 2007

Boy Living in Bubble Develops Leukemia From Experimental Therapy

Tuesday , December 18, 2007

One of the first children in Britain to receive pioneering gene therapy for an immune system disorder has developed leukemia as a result of his treatment.

The boy, 3, is the first gene therapy patient in Britain to fall ill with leukemia, a known risk of the treatment. A similar gene therapy program in France has caused four cases of the blood cancer, and one death.

The child, who has not been named, was born with X-linked severe combined immunodeficiency (X-SCID), a genetic condition in which the immune system fails to develop. It is often known as “bubble baby syndrome,” as sufferers are shielded against germs in a sterile pouch.

Two years ago, he became the eighth patient to be treated with the gene therapy program at the U.K.’s Great Ormond Street Hospital. The program uses a genetically modified virus to correct the faulty DNA that causes X-SCID.

His immune system responded “extremely well” to the procedure but leukemia was diagnosed last month, the hospital said. This is an acknowledged risk of gene therapy, as inserting the replacement DNA can trigger another gene that promotes cancer.

None of the other 14 children to have had gene therapy for X-SCID and a similar condition, known as ada-SCID, has developed leukemia so far, the hospital said. The cancer, however, has been diagnosed in four of the 11 patients involved in a French trial, one of whom has died while three are in remission.

Professor Adrian Thrasher and professor Bobby Gaspar, who treated the boy, said in a statement: “Our first thoughts are to secure the best treatment for this child and to support his family at this very difficult time. This unfortunate event is the first such development on our program. As with any medical treatment there are associated side-effects. The development of leukemia is now a recognized side-effect in this study, though the risks are balanced by the severity of the condition and the lack of good alternative treatments for X-SCID.

They pointed out that 80 percent of children with leukemia made a full recovery, and there was every chance that the child would survive the cancer and be cured of X-SCID.

The immune system disorder is always fatal without treatment. The only alternative to gene therapy is a bone marrow transplant, which rarely achieves satisfactory results unless a fully matching donor is available.

linkback url: http://www.foxnews.com/story/0,2933,317225,00.html


‘Bubble boy’ develops leukaemia

December 18, 2007

‘Bubble boy’ develops leukaemia

One of the boys with no immune system being treated with pioneering gene therapy at Great Ormond Street has developed leukaemia, his doctors say. They said cancer was an “acknowledged risk” of this treatment for X-SCID, which is commonly known as “boy in the bubble syndrome”.

A trial in France of a similar therapy was halted in 2002 after four of eleven children developed leukaemia.

Ten children with X-SCID have so far been treated at the London hospital.

  Gene therapy appears to offer a less intrusive treatment, for those patients without a good bone marrow donor, and if we continue to make advances, may become the treatment of choice.
Great Ormond Street

All of these children “have seen clinical benefit”, Professor Adrian Thrasher and Professor Bobby Gaspar, consultant immunologists on the gene therapy programme, said in a statement.

“This unfortunate event is the first such development on our programme.”

X-SCID is caused by mutations in the IL2RG gene, which governs the behaviour of a protein involved in the development of a number of immune system cells.

Without the protein, the cells cannot develop normally, and are unable to protect the body.

The gene therapy works by replacing a defective gene.

Prior to treatment, the outlook for children with X-CID who did not have a suitable bone marrow donor was bleak.

They had to live in sterile conditions or risk picking up a life-threatening infection. They often died very young.

French findings

But there had been warnings that there was a risk of cancer.

A US study last year published last year looked at the long-term effect of infecting the IL2RG gene into mice: A third of the animals developed a form of cancer, with most doing so when they were about 10 months old.

A few years previously a French trial was halted prematurely after three of ten boys treated were diagnosed with T-Cell leukaemia.

Nine of them had been cured of their original condition. Three went on to be cured from leukaemia, but one died.

Last year, doctors at Great Ormond Street dismissed the findings of the US study as “unhelpful”.

Making improvements

Great Ormond Street said what they hoped would be safer formulations of the genetic medicine were being prepared for clinical trials next year at several centres.

“Every child matters,” they said in a statement.

“Families are counselled very carefully before taking part in these treatments. Gene therapy appears to offer a less intrusive treatment, for those patients without a good bone marrow donor, and if we continue to make advances, may become the treatment of choice.

“All patients are monitored carefully as part of their care plan.”

Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/7149463.stm

Published: 2007/12/18 09:59:26 GMT

© BBC MMVII

linkback url: http://news.bbc.co.uk/2/hi/health/7149463.stm


Gene therapy cancer case

December 18, 2007

Q&A: Gene therapy cancer case

A child on the gene therapy programme at Great Ormond Street Hospital for Children NHS Trust has developed leukaemia, two years after treatment. The child had been successfully treated for X-SCID, a condition which leaves the patient unable to fight off infection and disease.

What is X-SCID?

It stands for X-linked Severe Combined Immunodeficiency, and is also known as “bubble boy” disease.

Children born with the condition, which is caused by a single mutated gene, have no immune system

They must live in sterile conditions or risk picking up a life-threatening infection.

Why was gene therapy developed for X-SCID?

X-SCID is fatal unless treated. The conventional treatment is bone marrow transplantation, which has excellent results with a full matched donor, but less satisfactory results with a poorer match.

Only one third of X-SCID patients will have a fully matched donor.

Bone marrow transplantation involves powerful chemotherapy and up to 20% of children transplanted with a less than full match die.

Gene therapy has therefore been a highly valuable treatment option for this group of children.

How does gene therapy work?

In gene therapy, a working copy of the defective gene is placed in the child’s own bone marrow cells and these are then returned to the child.

The gene is placed in the cells using a vector, a modified virus.

Modified cells grow rapidly and ensure that the child’s immune function returns, sometimes completely.

Why is there a risk of leukaemia?

A similar X-SCID trial in Paris led to a number of children developing leukaemia (four cases from 11 treated).

Three were treated and recovered, one died.

There is no doubt in the Paris cases that the leukaemia was caused by the gene therapy, where the introduced gene was implanted next to, and switched on, an oncogene (a cancer causing gene).

The three other children are in remission from leukaemia, their immune systems are now working again, and they are doing very well.

Great Ormond Street has conducted a number of molecular tests and says it can demonstrate that the case of leukaemia on its trial was also caused by the gene therapy.

The actual mechanism is similar to the cases in Paris and further work is ongoing.

Did the families know the risks?

Yes. Families are carefully counselled about the possible risks, and since the first Paris case, this has included discussion of the possibility of leukaemia.

Great Ormond Street said it was “extremely thorough” in seeking fully informed consent and all the families have been aware of the risk before entering the study.

In every case, the hospital required the approval of the regulator before treating a patient and a number of children including the present case received independent counselling from an independent specialist.

What are the prospects for the children who get leukaemia?

Leukaemia is a very serious illness but can be treated and success rates now exceed 80%.

Is it worth persevering with gene therapy?

Great Ormond Street argues that taking its results and Paris’ together, present indications are that gene therapy is still safer and less intrusive than the conventional treatment, for those children without a good bone marrow donor match.

The hospital has pledged to continue to try to minimise risks to patients through protocols and better design.

The current gene therapy treatment for X-SCID is being replaced by a new vector which has been designed to reduce the risk.

There are no plans to use our old vector to treat future children.

Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/1/hi/health/7149460.stm

Published: 2007/12/18 09:48:54 GMT

© BBC MMVII

linkback url: http://news.bbc.co.uk/1/hi/health/7149460.stm


Fighting ‘bubble boy disease’ among Navajos, Apaches

December 15, 2007

Fighting ‘bubble boy disease’ among Navajos, Apaches

— Lorria Trujillo never felt she knew enough to question doctors about her 6-month-old daughter’s health. She didn’t second guess them when they insisted Charlotte merely had a viral infection after months of being sick; she didn’t question them when the girl’s lungs collapsed.

Trujillo watched as her baby was unhooked from life support and held her until she died.

That was 1995.

Written on the child’s death certificate is “severe infection,” but Trujillo now knows the condition that claimed her daughter’s life is the same one her 9-year-old daughter, Grace Marie Yazzie, suffers from.

“With most families, it’s the mother that’s really responsible for taking care of their babies,” the Navajo woman said. “I really felt like I didn’t do my part as a mother, and I kept looking for something I would have missed. Would I have known?”

Without treatment, children have no chance of surviving severe combined immune deficiency — a disorder that’s more commonly referred to as “bubble boy disease” after a Houston boy who was forced to spend his 12-year life in a plastic bubble free of germs.

In the Navajo population, one in every 2,500 children inherit SCID, a condition that endows them virtually no immune system. In the general population, SCID is much more rare, affecting one in 100,000 children.

Before Grace was born, Trujillo had researched SCID, and knowing that she and her now ex-husband had a one-in-four chance of having another baby with the condition, she insisted on a blood test. Although doctors didn’t think the test was necessary, Trujillo knew not to keep quiet this time around.

“The longer it took, the more apprehensive I got,” Trujillo said. “When I saw the doctor come into the delivery room, I could tell there was something wrong. He told me, ‘Yeah, she tested positive for SCID.’ “

Prior to the late 1970s, the illness baffled doctors working with Navajo children. Over generations, families would lose children without explanation.

Morton Cowan, a physician who has worked with SCID patients for more than two decades, encountered his first case in the mid-1980s when he was asked to watch over Navajo patients for a doctor in Denver who went on sabbatical.

To Cowan, the disease appeared to be linked to genes, so in 1986 he and a research geneticist decided over lunch to find the gene — a quest that would take 15 years, Cowan said.

“When we ultimately found the gene and went back, we were able to show that it was the same gene mutation in every Navajo and Apache child that had the disease,” Cowan said.

American Indians typically have had a higher infant-mortality rate than other ethnic groups because of poverty and limited access to medical care, said Diana Hu, chief pediatrician on the 27,000-square-mile Navajo Nation. So when an infant died of infection, “you don’t really notice that is odd,” because others also were dying of infection, she said.

Things changed in the late 1970s and early 1980s with improvements to health care.

“This is not just kids dying; this is something odd,” Hu recalls thinking. “When you start to lower your infant-morality (rate), you start to notice when kids die.”

But detecting the disorder wasn’t easy. What can frustrate parents is that the symptoms of SCID aren’t much different from the common cold or flu. Normal kids can have numerous ear infections in a year but are treated with antibiotics and the infection goes away.

In SCID patients, the infection lingers and worsens.

Researchers have identified about a dozen genes that cause SCID. Cowan, director of the Pediatric Bone Marrow Transplant Program at the University of California-San Francisco, says Navajos and Apaches suffer from the most severe form of the disorder in which they lack a gene called Artemis. Without it, the children’s bodies aren’t able to repair DNA or develop disease-fighting T cells and B cells.

“These kids are the most difficult to treat,” he said.

The autosomal recessive gene found in the Navajo and Apache populations can be passed from one generation to the next without harm. But when two people who carry the gene have children together, there’s a one-in-four chance their children will be born with SCID. The type seen in the Navajos and Apaches is known as SCIDA, because the two groups share a common language root, Athabascan.

• • •

The disorder is something Lynnae Redhouse and Sean Frank, a young Navajo couple, never had heard of.

Day after day, their son, also Sean Frank, would cough until he turned blue and sleep more than a baby should. His hands and feet shook, and soon after he was fed, the milk would come right back up.

Redhouse and Frank knew it was normal for a child to occasionally get sick, but something here wasn’t right.

“It turned into just a routine of waking up all the time for him, because we were so worried he wouldn’t wake us up at all,” said his father.

Each time Redhouse and Frank would seek care for their son, the doctors’ message was the same: Take him home; he’s fine.

It turns out he wasn’t fine, and not until the child was taken to University of New Mexico Hospital did his parents find out their son has SCIDA.

“We never thought anything like this would happen to us. In my heart, when I heard that result, we thought, ‘No, he’s a healthy baby,’ ” Redhouse said. “He just didn’t look like he had SCID. People would say to us, ‘He’s not losing weight; he doesn’t have skin rashes.’ “

Bone-marrow transplants can be a lifesaver for children who suffer from SCIDA, providing them with stem cells that take root and begin producing T cells. But even with the best care, not all children will be saved.

Shortly after receiving a transplant this summer, Sean’s cells are growing, “just a little bit,” Redhouse says, but it could be months before he can return to his home in Farmington, on the edge of the Navajo reservation.

“He has to have a certain number before he gets to go,” said Redhouse from San Francisco, where Sean is being treated.

At a clinic each week, doctors weigh Sean, take his temperature, blood samples, and check for any rashes, changes in behavior or sleeping patterns.

Because SCIDA patients lack the Artemis gene, Cowan and his team have decided not to prep the patients for bone marrow transplants using the standard approaches, such as radiation or chemotherapy, which break down DNA in order to rebuild the immune system.

“It turned out that was extremely dangerous for the Navajo SCID babies,” said Jennifer Puck, who studies inherited immune deficiency disorders at UCSF. “In fact, many of them died before the transplant could be given to them because of the toxicity from the radiation treatment.”

• • •

On a recent day at the Tuba City Regional Medical Center, 8-year-old Justin Knight is playing with action figures as he awaits a bimonthly reunion with two other SCIDA patients.

Inside the infusion room, Trujillo’s 9-year-old daughter, Grace, rants about her favorite sports, how much she likes math and what she has learned from having SCIDA nearly a decade after being diagnosed.

“Take medicine and eat the right food,” she jokingly says, holding up a candy bar. “Chocolate keeps me going.”

A chair opens up nearby, and Justin enters the room.

He and fellow boarding-school classmate Joron Mike stare up at the TV, seemingly oblivious to everything else.

Grace and the boys each have a port-a-cath, a direct conduit to a major blood vessel — implanted in their chest. Prolonging their lives is a two-hour infusion of gamma globulin to reinforce their B cells. Once diagnosed with SCIDA, most patients at the Tuba City hospital are sent hundreds of miles from their homes on the reservation to UCSF Children’s Hospital to undergo transplants.

“These kids just didn’t happen to fully take with the bone marrow,” said Mary Schillo, an infusion nurse at the hospital. “They will have to do this for the rest of their lives.”

Grace pulls out a rubber band wrapped around her dark brown pony tail and reveals a white patch of hair. She boasts about a Mickey Mouse-shaped discoloration on her back. Parts of her fingers and around her mouth also are lighter than the rest of her skin.

She asks her mother she’s like this and nobody else is, why she’s shorter than other children; says other kids make fun of her, Trujillo said.

“It’s kind of hard for her to understand why kids would be mean,” Trujillo said. “I just have to tell her, ‘It’s not your fault. Some kids are different. They think differently.’ “

Researchers aren’t sure why some SCIDA patients never lose their baby teeth, are shorter than other children or have severe oral and genital ulcerations. One theory is that the lack of Artemis could be responsible.

As dinner trays are set down on tables for Grace, Joron, Justin and family members who accompany them to the hospital, they are told to wash their hands.

Germs are their enemies.

While most kids are making mud pies and snowmen, these children are urged to stay away from things that can trigger an infection. A fever or diarrhea could mean a trip to the emergency room.

• • •

About 3,500 babies are delivered each year at hospitals on the Navajo Nation.

A hospital policy manual Hu developed outlines what diseases commonly are seen on the Navajo Nation and what to do if a health provider suspects SCIDA.

“Most of us have been here for 10 years and have seen it happen,” Hu said. Others, she said, “will have read about this stuff but never seen it.”

Cowan said there are continued efforts to educate new doctors on the reservation about what to look for, especially because SCID is diagnosed at a much higher rate on the Navajo Nation than elsewhere.

“Even with that,” he says, children “sometimes slip through.”

Hu wonders whether children she has seen die would have lived if diagnosed earlier.

“Our kids who are diagnosed earlier and transplanted earlier tend to do better,” she said. “Our goal is to spare families from this tragedy.”

linkback url: http://www.abqtrib.com/news/2007/dec/15/
fighting-bubble-boy-disease-among-navajos-apaches/


Inclement weather hampers ill girl’s flight to get treatment

December 12, 2007

 

Web Exclusive: Inclement weather hampers ill girl’s flight to get treatment

 

12/12/2007, 8:38 am


By Janet Cremer
janetcremer@daily-journal.com
815-937-3384

For many, the sleet and rain that has hit the area is no more than a commuter’s annoyance, but for Balei Chinski it may be a matter of life and death.

The Bourbonnais teen has a rare immune deficiency disease, which leaves her unable to fight off infections. She was scheduled to take off this morning from the Greater Kankakee Airport to fly to Duke University in North Carolina to see a specialist. However, the weather is again hampering things.

“It took us two years to get this appointment,” Balei’s mother, Cheryl Chinski, said of the visit with a doctor she called, the “premier immune deficiency doctor in the world.”

The appointment at Duke is set for 9:30 a.m. Thursday. If Balei can’t make the appointment, she’ll need to wait until Jan. 3, according to Dr. Rebecca Buckley’s office.

The family is hopeful doctors at Duke will stabilize Balei’s precarious condition. “An infection or aneurysm will cause my child to die or not to be able to function as she is,” Chinski said.

Balei who has Undefined Severe Combined Immunodeficiency (SCID), was to take an Angel Flight, a nonprofit network of private pilots who provide free air transportation for families who need specialized medical treatment.

The only drawback to the generous service is that the private planes are usually smaller and can’t fly at higher altitudes, so flights are more likely to be canceled in bad weather.

Traveling by car isn’t possible, Chinski said, because sitting for long periods is physically difficult for Balei, who also suffers from juvenile rheumatoid arthritis and blood clots.

Angel Flights tried to arrange free transportation aboard a commercial airliner have been put off for fear they, too, could be canceled due to the weather.

Chinski whose story has been followed in The Daily Journal just doesn’t have time to waste. Amazingly, Balei has managed to make the honor roll at Bourbonnais Upper Grade Center, where she’s a seventh-grader. She’s tutored five hours a day.

“My baby missed half of first grade, half of third grade and most of this year because of strokes,” Chinski said. “These are strokes that paralyze and physically impair her.”

“She wants to be pediatrician,” Chinski said. “She tells me, ‘I know how sick kids feel, and I know what it’s like to be scared.’ ”

Complications from Balei’s disease puts her in the hospital several times a year. In fact, a serious infection hospitalized her twice in the last week. She also suffers from strokes.

“There’s an urgency starting to come on,” she said of her daughter’s condition. “The time when she’s healthy is starting to narrow. And the length of time that she’s sick is getting longer.”
Benefit planned

Insurance will not cover Balei Chinski’s medical procedures at Duke University. A benefit is being planned for 1 p.m. to 11 p.m., March 1 at the Kankakee VFW.

Contributions to the “Balei Chinski Benefit Fund” may be sent to: People’s Bank, 315 Main St. NW, Bourbonnais, IL 60914.

linkback url: http://daily-journal.com/archives/dj/display.php?id=409635


Universal Newborn SCID Screening Proposed

December 11, 2007

Universal Newborn SCID Screening Proposed

As a young researcher in training during the 1980s, Jennifer Puck, MD, helped care for the well-known “boy in the bubble,” who lived in germ-free isolation because of SCID, or severe combined immunodeficiency. Today, researchers know that SCID actually encompasses more than 12 known single-gene disorders that interfere with immune function. Children with SCID are born with faulty immune systems and can die from routine infections.

Today, these patients can be provided with functional immune systems through hematopoietic stem cell transplantation. The best outcomes for the therapy occur when transplantation takes place during the first days or weeks of life, before infections have occurred.

But early diagnosis of the condition often eludes physicians, said Puck, now a UCSF professor of pediatrics and human genetics and medical director of the Pediatric Clinical Research Center at UCSF Children’s Hospital. “The infections that SCID infants are suffering are simply not distinguishable early on from routine infections in otherwise healthy individuals,” she said.

In an article published in the December 2007 issue of Current Opinion in Allergy and Clinical Immunology, Puck reports that a consortium of physicians – called the SCID Newborn Screening Working Group – from throughout the country is now moving toward establishing universal screening of newborns for SCID.

“Because most SCID babies do not have a family history that alerts their doctors of their condition, we need other means for earlier diagnosis of cases, allowing for optimal treatment,” Puck said. “One test for SCID now being proposed would use the dried blood spots that already are collected from newborns for other genetic evaluations.

“Early recognition by pre-symptomatic screening would afford the ideal opportunity for effective treatment to achieve the best possible outcomes,” Puck said.

Neonatal screening for severe combined immune deficiency
Jennifer M Puck
Current Opinion in Allergy and Clinical Immunology (vol. 7, issue 6, Dec. 2007)
Abstract

 

linkback url: http://pubaffairs.ucsf.edu/today/cache/feature/200712102.html

 


Transplant boy is out of bubble

December 10, 2007

Transplant boy is out of bubble

A six-year-old boy is able to leave hospital seven weeks after receiving a bone marrow transplant from a donor in the United States. Rhys Harris of Newbridge, Caerphilly county, is one of only about 40 people in the world with Nemo, a genetic disease crippling his immune system.

He has spent months in a sterile bubble at a hospital in Newcastle because he could not fight off infection.

The bone marrow will help him build a new immune system.

Rhys, his parents Kevin and Dawn and younger brother Morgan moved from south Wales to Newcastle, where the treatment took place, after a worldwide search for a donor.

The family have already been able to enjoy a day trip to the seaside from the hospital.

Mr Harris said: “It’s earlier than ever we thought we could come out with him - it’s great to see him running about, and he really needs to strengthen his feet and start his muscles working again.

“He’s seeing all these things he can’t remember before, like buses, Christmas trees in people’s windows - he sees a dog and he smiles, it’s precious.”

The donated bone marrow was flown from America in October before the transplant took place.

The youngster’s immune system had to be destroyed by chemotherapy before the bone marrow transplant could take place.

Rhys, who is deaf following a bout of meningitis, will have to live in a special germ-free room for 12 months and have restricted contact while his immune system rebuilds.

“We have to be very careful about where we go with him and for how long, but it’s nice to get out in the fresh air after so long,” said Mr Harris.

You can see more of Rhys’ story on BBC Wales Today on BBC1 Wales at 1830 GMT on Monday.

Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/uk_news/wales/south_east/7135523.stm

Published: 2007/12/10 07:09:38 GMT